BioMarin Pharmaceutical
BMRN
$97.24
Share price
2.05%
Change (1 day)
24.84%
Change (1 year)
Categories
Revenue for BioMarin Pharmaceutical (BMRN)
Revenue in 2022 (TTM): $2.09 B
According to BioMarin Pharmaceutical's latest financial reports the company's current revenue (TTM) is $2.09 B. In 2021 the company made a revenue of $1.84 B a decrease over the years 2020 revenue that were of $1.86 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BioMarin Pharmaceutical from 2001 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $2.09 B | 13.53% |
| 2021 | $1.84 B | -0.76% |
| 2020 | $1.86 B | 9.18% |
| 2019 | $1.70 B | 14.27% |
| 2018 | $1.49 B | 13.52% |
| 2017 | $1.31 B | 17.62% |
| 2016 | $1.11 B | 25.4% |
| 2015 | $0.89 B | 18.59% |
| 2014 | $0.75 B | 36.93% |
| 2013 | $0.54 B | 9.54% |
| 2012 | $0.50 B | 13.45% |
| 2011 | $0.44 B | 17.3% |
| 2010 | $0.37 B | 15.9% |
| 2009 | $0.32 B | 9.5% |
| 2008 | $0.29 B | 143.86% |
| 2007 | $0.12 B | 44.38% |
| 2006 | $84.2 M | 228.05% |
| 2005 | $25.66 M | |
| 2002 | $13.91 M | 18.98% |
| 2001 | $11.69 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $47.62 B | 2,172.18% | 🇫🇷 France |
 Ultragenyx RARE | $0.36 B | -82.67% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $0.11 B | -94.69% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | $75.47 M | -96.40% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | $0.32 B | -84.29% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | $0.19 B | -90.85% | 🇺🇸 USA |